Datasheet

CTHRC1 Antibody
CATALOG NUMBER: 8101

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:CTHRC1 antibody can be used for detection of CTHRC1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1468 - Rat Small Intestine Tissue Lysate
 2) Cat. No. 11-801 - Human Small Intestine Tissue Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 27 kDa

Observed: 27 kDa
SPECIFICITY:CTHRC1 antibody is human, mouse and rat reactive. At least two isoforms of CTHRC1 are known to exist; this antibody will detect only the larger isoform.
IMMUNOGEN:CTHRC1 antibody was raised against a 19 amino acid peptide near the amino terminus of human CTHRC1.

The immunogen is located within the first 50 amino acids of CTHRC1.
HOST SPECIES:Rabbit

Properties

PURIFICATION:CTHRC1 antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:CTHRC1 antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CTHRC1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:Collagen triple helix repeat-containing protein 1
ACCESSION NO.:NP_612464
PROTEIN GI NO.:19923989
OFFICIAL SYMBOL:CTHRC1
GENE ID:115908

Background

BACKGROUND:The Collagen triple helix repeat-containing protein (CTHRC1) is a glycosylated, secreted protein that is transiently expressed in the arterial wall in response to injury where it is thought to contribute to vascular remodeling by inhibiting collagen expression and deposition and promoting cell migration (1). CTHRC1 is highly expressed multiple human cancers, including pancreatic cancer where it plays a significant role in the progression and metastasis of the disease by regulating migration and adhesion of tumors cells (2). CTHRC1 overexpression can also be used as an independent prognostic marker in gastric cancer (3). Mutations at this locus have been associated with Barrett esophagus and esophageal adenocarcinoma (4).
REFERENCES: 1) Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ. Res. 2005; 96:261-8.
2) Park EH, Kim S, Jo JY, et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 2013; 34:694-702.
3) Gu L, Liu L, Zhong L, et al. Cthrc1 overexpresion is an independent prognostic marker in gastric cancer. Hum. Pathol. 2014; 45:1031-8.
4) Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306:410-9.

For Research Use Only